MCID: PHC013
MIFTS: 44

Phaeochromocytoma

Categories: Cancer diseases

Aliases & Classifications for Phaeochromocytoma

MalaCards integrated aliases for Phaeochromocytoma:

Name: Phaeochromocytoma 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0050771

Summaries for Phaeochromocytoma

MalaCards based summary : Phaeochromocytoma is related to multiple endocrine neoplasia, type iia and thyroid carcinoma, familial medullary. An important gene associated with Phaeochromocytoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Carbon metabolism and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include testes, thyroid and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Phaeochromocytoma

Diseases related to Phaeochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iia 32.0 NF1 RET SDHB SDHD
2 thyroid carcinoma, familial medullary 30.1 CHGA RET SST
3 somatostatinoma 29.7 CHGA SST
4 gastrinoma 29.6 CHGA SST
5 multiple endocrine neoplasia 29.6 CHGA NF1 RET SDHB SDHC VHL
6 neurofibromatosis, type iv, of riccardi 29.0 NF1 RET SDHB SDHC SDHD SST
7 von hippel-lindau syndrome 28.8 CHGA NF1 NPY RET SDHB SDHC
8 paraganglioma 28.3 CHGA NF1 RET SDHAF2 SDHB SDHC
9 multiple endocrine neoplasia, type iib 11.0
10 pancreatic serous cystadenoma 10.4 CHGA VHL
11 glomus tumor 10.4 SDHB SDHD
12 epithelioid malignant peripheral nerve sheath tumor 10.4 CHGA NF1
13 gastrointestinal neuroendocrine benign tumor 10.3 CHGA SST
14 gastric neuroendocrine neoplasm 10.3 CHGA SST
15 adenoma of the pancreas 10.3 CHGA SST
16 spinal canal and spinal cord meningioma 10.3 CHGA NF1
17 glucagonoma 10.3 CHGA SST
18 hyperinsulinemic hypoglycemia, familial, 2 10.3 CHGA SST
19 malignant glandular tumor of peripheral nerve sheath 10.3 NF1 SST
20 vipoma 10.3 CHGA SST
21 duodenal somatostatinoma 10.3 NF1 SST
22 pancreatoblastoma 10.3 CHGA SST
23 paragangliomas 1 10.3 SDHB SDHC SDHD
24 carney triad 10.3 SDHB SDHC SDHD
25 paraganglioma and gastric stromal sarcoma 10.3 SDHB SDHC SDHD
26 chondroma 10.3 SDHB SDHC SDHD
27 spinal meningioma 10.3 CHGA NF1
28 acute thyroiditis 10.2 CHGA POMC
29 binswanger's disease 10.2 CHGA SST
30 zollinger-ellison syndrome 10.2 CHGA SST
31 syndrome of inappropriate antidiuretic hormone 10.2 CHGA POMC
32 bronchus adenoma 10.2 POMC SST
33 bronchial adenomas/carcinoids childhood 10.2 POMC SST
34 familial renal papillary carcinoma 10.2 NGF RET
35 acidophil adenoma 10.2 POMC SST
36 pituitary infarct 10.2 POMC SST
37 cervix small cell carcinoma 10.2 CHGA POMC
38 chiasmal syndrome 10.2 POMC SST
39 cortical thymoma 10.2 NGF SST
40 prolactin producing pituitary tumor 10.1 NGF SST
41 hypertrophic pyloric stenosis 10.1 RET SST
42 pancreatic gastrinoma 10.1 CHGA SST
43 carcinoid tumors, intestinal 10.1 CHGA SDHD SST
44 nelson syndrome 10.1 POMC SST
45 hyperpituitarism 10.1 POMC SST
46 thyroid cancer, nonmedullary, 2 10.1 CHGA RET SST
47 neuroendocrine tumor 10.1 CHGA SDHD SST
48 breast papillary carcinoma 10.1 CHGA RET
49 functioning pituitary adenoma 10.1 POMC SST
50 neuroblastoma 10.1

Graphical network of the top 20 diseases related to Phaeochromocytoma:



Diseases related to Phaeochromocytoma

Symptoms & Phenotypes for Phaeochromocytoma

GenomeRNAi Phenotypes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.8 VHL NF1 RET SDHD
2 Decreased viability GR00221-A-2 9.8 VHL NF1 RET SDHD
3 Decreased viability GR00221-A-4 9.8 NF1 RET SDHD
4 Decreased viability GR00231-A 9.8 RET
5 Decreased viability GR00301-A 9.8 VHL RET
6 Decreased viability GR00381-A-1 9.8 SDHD
7 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 VHL NF1

MGI Mouse Phenotypes related to Phaeochromocytoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 RET NF1 SDHD NGF SDHB SST
2 growth/size/body region MP:0005378 10.09 NF1 RET SDHD NGF SST NPY
3 cardiovascular system MP:0005385 10.08 NF1 RET SDHD NGF SDHB POMC
4 mortality/aging MP:0010768 10.02 NF1 RET SDHD NGF SST SDHB
5 hematopoietic system MP:0005397 10.01 POMC VHL SDHC NF1 RET SDHD
6 endocrine/exocrine gland MP:0005379 10 VHL CHGA NF1 RET SDHD SDHB
7 neoplasm MP:0002006 9.73 NF1 RET SDHD SDHB POMC VHL
8 no phenotypic analysis MP:0003012 9.7 RET NGF SDHB SST TMEM127 POMC
9 normal MP:0002873 9.56 RET NF1 SDHD NGF SDHB SST
10 renal/urinary system MP:0005367 9.17 RET NF1 SDHB NPY POMC VHL

Drugs & Therapeutics for Phaeochromocytoma

Drugs for Phaeochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 3,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 3,Phase 2
4 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
5 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
6 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
7 Antihypertensive Agents Phase 4,Phase 3,Phase 2
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
9 Vasodilator Agents Phase 4,Phase 3,Phase 2
10
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
11
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
12
Ifosfamide Approved Phase 3 3778-73-2 3690
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1
18 Hormone Antagonists Phase 2, Phase 3,Phase 1
19 Hormones Phase 2, Phase 3,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Isophosphamide mustard Phase 3 0
25 Topoisomerase Inhibitors Phase 3,Phase 2
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
29 Racepinephrine Approved Phase 2 329-65-7
30
Carbidopa Approved Phase 2 28860-95-9 38101 34359
31
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
34
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
35
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
37
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
38
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
39
Tamoxifen Approved Phase 2 10540-29-1 2733526
40
Melphalan Approved Phase 2 148-82-3 460612 4053
41
Pancrelipase Approved, Investigational Phase 2 53608-75-6
42
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
43
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
44
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
45
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
46
Lenvatinib Approved, Investigational Phase 2 417716-92-8
47
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
48
nivolumab Approved Phase 2 946414-94-4
49
Pembrolizumab Approved Phase 2 1374853-91-4
50
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551

Interventional clinical trials:

(show top 50) (show all 84)

# Name Status NCT ID Phase Drugs
1 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
9 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
12 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
13 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2 Sunitinib
14 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
15 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
16 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
20 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
21 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
22 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
23 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
24 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;Amino Acid solution
25 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
26 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
27 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
28 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2 MIBG
29 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2 PEN-221
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
32 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
33 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
34 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
35 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
36 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
37 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
38 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
39 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
42 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
43 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
44 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Unknown status NCT02186678
47 Evaluation of Plasma Catecholamine Concentration During Surgery Unknown status NCT00948181
48 Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Unknown status NCT02361996
49 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
50 Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing NCT00730444 Iobenguane I 123 Injection

Search NIH Clinical Center for Phaeochromocytoma

Genetic Tests for Phaeochromocytoma

Anatomical Context for Phaeochromocytoma

MalaCards organs/tissues related to Phaeochromocytoma:

38
Testes, Thyroid, Liver, Lung, Heart, Endothelial, Bone

Publications for Phaeochromocytoma

Articles related to Phaeochromocytoma:

(show top 50) (show all 626)
# Title Authors Year
1
Clinical evaluation and treatment of phaeochromocytoma. ( 29027806 )
2018
2
Pathology and genetics of phaeochromocytoma and paraganglioma. ( 29239044 )
2018
3
Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. ( 29332973 )
2017
4
Hypertensive emergency masquerading as phaeochromocytoma: a report of two cases. ( 28784870 )
2017
5
Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis. ( 28911298 )
2017
6
Author's reply to Grocott: Risk of cardiac ischaemia in patients without I+-receptor blockade for phaeochromocytoma surgery. ( 28969332 )
2017
7
Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas. ( 28693800 )
2017
8
Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma? ( 27696513 )
2017
9
The clinical genetics of phaeochromocytoma and paraganglioma. ( 29166454 )
2017
10
A rare cause of hypertension in pregnancy: Phaeochromocytoma. ( 28680468 )
2017
11
Phaeochromocytoma and Paraganglioma Excision Involving the Great Vessels. ( 28856331 )
2017
12
A laparoscopic revelation: incidental nodule in a patient with bilateral phaeochromocytoma in multiple endocrine neoplasia Type 2A. ( 29242944 )
2017
13
Giant phaeochromocytoma presenting with an acute stroke: reappraising phaeochromocytoma surveillance for the neurofibromatosis type 1 phakomatosis. ( 29102976 )
2017
14
Perioperative I+-receptor blockade in phaeochromocytoma surgery: an observational case series. ( 28100521 )
2017
15
Perioperative management of a large, late presenting phaeochromocytoma. ( 28100576 )
2017
16
Significant decreases in blood propofol concentrations during adrenalectomy for phaeochromocytoma. ( 28548279 )
2017
17
Optimal Management of a Synchronous Diagnosis of Phaeochromocytoma and Colorectal Neoplasia. ( 29203998 )
2017
18
Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. ( 28605116 )
2017
19
Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis. ( 28746746 )
2017
20
Concomitant multiple myeloma and probable phaeochromocytoma in a cat. ( 28839945 )
2017
21
Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. ( 28179334 )
2017
22
Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. ( 27856506 )
2017
23
Safety assessments in the avoidance of preoperative I+-receptor blockade in phaeochromocytoma surgery: the pitfalls of a zero numerator. ( 28969333 )
2017
24
Cardiogenic shock induced by a voluminous phaeochromocytoma rescued by concomitant extracorporeal life support and open left adrenalectomy. ( 27068551 )
2016
25
Phaeochromocytoma presenting with ST segment elevation myocardial infarction. ( 26857585 )
2016
26
Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. ( 26839173 )
2016
27
Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: is it always necessary? ( 27864838 )
2016
28
Phaeochromocytoma and transient left ventricular apical ballooning syndrome. ( 27505337 )
2016
29
Phaeochromocytoma and Paraganglioma. ( 27888488 )
2016
30
Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. ( 27075351 )
2016
31
Rapid-sequence MRI for long-term surveillance for paraganglioma and phaeochromocytoma in patients with succinate dehydrogenase (SDHx) mutations. ( 27634942 )
2016
32
Unusual presentation of phaeochromocytoma. ( 27166010 )
2016
33
Occurrence of phaeochromocytoma tumours in RET mutation carriers - a single-centre study. ( 26884116 )
2016
34
Phaeochromocytoma presenting as an acute coronary syndrome. ( 27797837 )
2016
35
Recurrence of phaeochromocytoma in pregnancy in a patient with multiple endocrine neoplasia 2A: a case report and review of literature. ( 27808580 )
2016
36
Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A. ( 27994876 )
2016
37
Phaeochromocytoma presenting with labile blood pressures following coronary artery bypass grafting. ( 27699857 )
2016
38
Successful management of phaeochromocytoma in the third trimester of pregnancy with the use of rapid sequential alpha-adrenergic blockage. ( 26792534 )
2016
39
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. ( 27048283 )
2016
40
Bowel perforation complicating an ACTH-secreting phaeochromocytoma. ( 28203371 )
2016
41
Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. ( 27194370 )
2016
42
Primary hypercortisolism and phaeochromocytoma next to, but not related to, each other. ( 27073149 )
2016
43
Inappropriate adrenoreceptor blockade prior to phaeochromocytoma removal is perhaps a 'timely reappraisal'? ( 27332792 )
2016
44
ANNALS EXPRESS: Single-centre study of the diagnostic performance of plasma metanephrines with seated sampling for the diagnosis of phaeochromocytoma/paraganglioma. ( 27170024 )
2016
45
Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. ( 26998836 )
2016
46
Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted/seated patients. ( 27166307 )
2016
47
Endoprosthetic reconstruction for metastatic phaeochromocytoma in the distal femur: A case report. ( 28018063 )
2016
48
Invasive phaeochromocytoma presenting as a right atrial mass. ( 26632094 )
2016
49
Malignant phaeochromocytoma with cavoatrial extension imaged with (123)I-MIBG. ( 26932713 )
2016
50
Neurofibromatosis-related phaeochromocytoma: two cases with large tumours and elevated plasma methoxytyramine. ( 26273474 )
2015

Variations for Phaeochromocytoma

Expression for Phaeochromocytoma

Search GEO for disease gene expression data for Phaeochromocytoma.

Pathways for Phaeochromocytoma

GO Terms for Phaeochromocytoma

Cellular components related to Phaeochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
2 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.8 SDHB SDHC SDHD

Biological processes related to Phaeochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.71 NGF NPY POMC SST
2 negative regulation of cell proliferation GO:0008285 9.67 NF1 SST TMEM127 VHL
3 aerobic respiration GO:0009060 9.46 SDHB SDHC
4 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.43 NF1 NGF
5 regulation of blood pressure GO:0008217 9.33 CHGA NPY POMC
6 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.32 NF1 RET
7 regulation of appetite GO:0032098 9.26 NPY POMC
8 mitochondrial electron transport, succinate to ubiquinone GO:0006121 9.13 SDHAF2 SDHC SDHD
9 tricarboxylic acid cycle GO:0006099 8.92 SDHAF2 SDHB SDHC SDHD

Molecular functions related to Phaeochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 NPY POMC SST
2 electron transfer activity GO:0009055 9.43 SDHB SDHC SDHD
3 neuropeptide hormone activity GO:0005184 9.37 NPY POMC
4 ubiquinone binding GO:0048039 9.16 SDHB SDHD
5 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.96 SDHB SDHD
6 succinate dehydrogenase activity GO:0000104 8.62 SDHC SDHD

Sources for Phaeochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....